Sandoz Wants Rapaflo Infringement Suit Trimmed

Law360, New York (August 21, 2013, 2:59 PM EDT) -- Sandoz Inc. on Monday asked a Delaware federal judge to trim a suit accusing its planned generic version of Actavis Inc.'s enlarged-prostate drug Rapaflo of infringing a patent covering the drug, saying the plaintiffs' claims were mostly speculative or barred by law.

According to Sandoz, its activities related to preparing its abbreviated new drug application for generic silodosin for submission to the U.S. Food and Drug Administration are protected under the Hatch-Waxman Act's safe harbor, while any allegations of future infringement by Actavis and other plaintiff...
To view the full article, register now.